Drug – bio-affecting and body treating compositions – Lymphokine – Interferon
Reexamination Certificate
2005-07-22
2010-02-16
Landsman, Robert (Department: 1646)
Drug, bio-affecting and body treating compositions
Lymphokine
Interferon
C530S351000, C514S002600
Reexamination Certificate
active
07662369
ABSTRACT:
Stabilized pharmaceutical formulations comprising IFN-β and highly purified mannitol are provided. The highly purified mannitol stabilizes the compositions by reducing the formation of IFN-β adducts in comparison with IFN-β formulated with mannitol that has not been highly purified. Methods for increasing the stability of IFN-β or a variant thereof in a liquid or lyophilized composition and for increasing storage stability of such a composition are also provided.
REFERENCES:
patent: 4439181 (1984-03-01), Blackshear et al.
patent: 4462940 (1984-07-01), Hanisch et al.
patent: 4465622 (1984-08-01), Nobuhara et al.
patent: 4605555 (1986-08-01), Sato et al.
patent: 4605556 (1986-08-01), Sato et al.
patent: 4647454 (1987-03-01), Cymbalista
patent: 4675184 (1987-06-01), Hasegawa et al.
patent: 4808705 (1989-02-01), Ferris
patent: 4816440 (1989-03-01), Thomson
patent: 4894330 (1990-01-01), Hershenson et al.
patent: 4992271 (1991-02-01), Fernandes et al.
patent: 5004605 (1991-04-01), Hershenson et al.
patent: 5066786 (1991-11-01), Protasi et al.
patent: 5104651 (1992-04-01), Boone et al.
patent: 5151265 (1992-09-01), Hwang-Felgner et al.
patent: 5183746 (1993-02-01), Shaked et al.
patent: 5573777 (1996-11-01), Serpelloni et al.
patent: 5609868 (1997-03-01), Lowther et al.
patent: 5643566 (1997-07-01), Hanisch et al.
patent: 5702699 (1997-12-01), Hanisch et al.
patent: 5762923 (1998-06-01), Gross et al.
patent: 5763409 (1998-06-01), Bayol et al.
patent: 6231851 (2001-05-01), Platz et al.
patent: 6479049 (2002-11-01), Platz et al.
patent: 6852314 (2005-02-01), Samaritani et al.
patent: 6887462 (2005-05-01), Shirley et al.
patent: 0 080 879 (1986-10-01), None
patent: 0 217 645 (1987-04-01), None
patent: 0 270 799 (1988-06-01), None
patent: 0 164 397 (1990-07-01), None
patent: 0 410 207 (1991-01-01), None
patent: 0 410 207 (1991-01-01), None
patent: 0 133 767 (1991-04-01), None
patent: 0 477 386 (1992-01-01), None
patent: 0 215 658 (1994-06-01), None
patent: 0 736 303 (1996-10-01), None
patent: 0 759 775 (1997-03-01), None
patent: 0 875 253 (1998-11-01), None
patent: WO 90/06762 (1990-06-01), None
patent: WO 91/16038 (1991-10-01), None
patent: WO 95/31213 (1995-11-01), None
patent: WO 95/31479 (1995-11-01), None
Anderson, et al., “Specific Binding of125I-Human Interferon-γ to High Affinity Receptors of Human Fibroblasts,”J. Biological Chemistry, 1982, pp. 11301-11304, vol. 257(19).
Czarniecki, et al., “Synergistic Antiviral and Antiproliferative Activities ofEscherichia coli-Derived Human Alpha, Beta, and Gamma Interferons,”J Virology, 1984, pp. 490-496, vol. 49(2).
Dubost, D.C. et al., “Characterization of a Solid State Reaction Product from a Lyophilized Formulation of a Cyclic Heptapeptide. A Novel Example of an Excipient-Induced Oxidation,”Pharmaceutical Research, Dec. 1996, pp. 1811-1814, vol. 13, No. 12.
Fellous, et al., “Interferon-Dependent Induction of mRNA for the Major Histocompatibility Antigens in Human Fibroblasts and Lymphoblastoid Cells,”Proc. Natl. Acad. Sci., 1984, pp. 3082-3086, vol. 79.
Herberman, et al., “Augmentation by Interferon Human Natural and Antibody-Dependent Cell-Mediated Cytotoxicity,”Nature, 1979, pp. 221-223, vol. 277.
Mark, et al., “Site-Specific Mutagenesis of the Human Fibroblast Interferon Gene,”Proc. Natl. Acad. Sci., 1984, pp. 5662-5666, vol. 81.
Williams, et al., “Natural Occurrence of 2-5A in Interferon-Treated EMC Virus-Infected L Cell,”Nature, 1979, pp. 582-586, vol. 282.
Hora Maninder S.
Wolfe Sidney N.
Hissong Bruce D
Landsman Robert
McAvoy Cozette M.
Novartis AG
LandOfFree
Stabilized interferon compositions does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Stabilized interferon compositions, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Stabilized interferon compositions will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4154947